Cargando…
New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal f...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418197/ https://www.ncbi.nlm.nih.gov/pubmed/22824057 http://dx.doi.org/10.1186/1471-2202-13-84 |
_version_ | 1782240607774703616 |
---|---|
author | Rose, Christiane Peoc’h, Katell Chasseigneaux, Stéphanie Paquet, Claire Dumurgier, Julien Bourasset, Fanchon Calon, Frédéric Laplanche, Jean-Louis Hugon, Jacques Allinquant, Bernadette |
author_facet | Rose, Christiane Peoc’h, Katell Chasseigneaux, Stéphanie Paquet, Claire Dumurgier, Julien Bourasset, Fanchon Calon, Frédéric Laplanche, Jean-Louis Hugon, Jacques Allinquant, Bernadette |
author_sort | Rose, Christiane |
collection | PubMed |
description | BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic target in AD research. To this end, very sensitive tests for preclinical and clinical research are required. METHODS: The tests are based on homogenous time-resolved fluorescence and require no washing steps. RESULTS: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These 20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models, and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium from 5 × 10(4) mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF. CONCLUSIONS: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies. |
format | Online Article Text |
id | pubmed-3418197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34181972012-08-14 New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease Rose, Christiane Peoc’h, Katell Chasseigneaux, Stéphanie Paquet, Claire Dumurgier, Julien Bourasset, Fanchon Calon, Frédéric Laplanche, Jean-Louis Hugon, Jacques Allinquant, Bernadette BMC Neurosci Methodology Article BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic target in AD research. To this end, very sensitive tests for preclinical and clinical research are required. METHODS: The tests are based on homogenous time-resolved fluorescence and require no washing steps. RESULTS: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These 20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models, and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium from 5 × 10(4) mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF. CONCLUSIONS: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies. BioMed Central 2012-07-23 /pmc/articles/PMC3418197/ /pubmed/22824057 http://dx.doi.org/10.1186/1471-2202-13-84 Text en Copyright ©2012 Rose et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Methodology Article Rose, Christiane Peoc’h, Katell Chasseigneaux, Stéphanie Paquet, Claire Dumurgier, Julien Bourasset, Fanchon Calon, Frédéric Laplanche, Jean-Louis Hugon, Jacques Allinquant, Bernadette New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title_full | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title_fullStr | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title_full_unstemmed | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title_short | New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease |
title_sort | new highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in alzheimer’s disease |
topic | Methodology Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418197/ https://www.ncbi.nlm.nih.gov/pubmed/22824057 http://dx.doi.org/10.1186/1471-2202-13-84 |
work_keys_str_mv | AT rosechristiane newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT peochkatell newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT chasseigneauxstephanie newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT paquetclaire newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT dumurgierjulien newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT bourassetfanchon newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT calonfrederic newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT laplanchejeanlouis newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT hugonjacques newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease AT allinquantbernadette newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease |